Dihydropyrimidine dehydrogenase levels in nonsmall-cell lung cancer tissues

[1]  T. Nukiwa,et al.  A phase II trial of oral UFT plus cisplatin (CDDP) in patients with non-small cell lung cancer (NSCLC). , 2001, Lung cancer.

[2]  N. Nagasue,et al.  Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. , 2000, International journal of oncology.

[3]  S. Groshen,et al.  Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[4]  S. Kudoh,et al.  UFT plus cisplatin combination chemotherapy in the treatment of patients with advanced nonsmall cell lung carcinoma , 2000, Cancer.

[5]  M. Fukushima,et al.  Dihydropyrimidine Dehydrogenase and Messenger RNA Levels in Gastric Cancer: Possible Predictor for Sensitivity to 5‐Fluorouracil , 2000, Japanese journal of cancer research : Gann.

[6]  M. Fukushima,et al.  Thymidylate synthetase and dihydropyrimidine dehydrogenase levels in gastric cancer. , 1999, Anticancer research.

[7]  M. Nishiyama,et al.  Dihydropyrimidine dehydrogenase, multidrug resistance-associated protein, and thymidylate synthase gene expression levels can predict 5-fluorouracil resistance in human gastrointestinal cancer cells. , 1999, International journal of oncology.

[8]  J. Sludden,et al.  Characterization of dihydropyrimidine dehydrogenase in human colorectal tumours. , 1998, British Journal of Cancer.

[9]  C. Mountain,et al.  Revisions in the International System for Staging Lung Cancer. , 1997, Chest.

[10]  R. Diasio,et al.  Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  H. Wada,et al.  Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. West Japan Study Group for Lung Cancer Surgery. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  O. Dassonville,et al.  Response to fluorouracil therapy in cancer patients: the role of tumoral dihydropyrimidine dehydrogenase activity. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  G. Wampler,et al.  A study of infusional cisplatin and infusional fluorouracil for locally advanced or metastatic non-small-cell lung cancer: a Mid-Atlantic Oncology Program study. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Y. Choong,et al.  The degradation of 5'-deoxy-5-fluorouridine by pyrimidine nucleoside phosphorylase in normal and cancer tissues. , 1985, Clinica chimica acta; international journal of clinical chemistry.

[15]  K. Ikenaka,et al.  Effect of coadministration of uracil or cytosine on the anti-tumor activity of clinical doses of 1-(2-tetrahydrofuryl)-5-fluorouracil and level of 5-fluorouracil in rodents. , 1979, Gan.

[16]  藤井 節郎.  Effect of Coadministration of Uracil or Cytosine on the Antitumor Activity of Clinical Doses of 1-(2-Tetrahydrofuryl)-5-Fluorouracil and Level of 5-Fluorouracil in Rodents , 1979 .